Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-511.9%
operating margin TTM
-519.75%
revenue TTM
150.35 Million
revenue per share TTM
0.69$
valuation ratios | |
|---|---|
| pe ratio | -8.19 |
| peg ratio | -0.08 |
| price to book ratio | 3.33 |
| price to sales ratio | 40.92 |
| enterprise value multiple | -11.15 |
| price fair value | 3.33 |
profitability ratios | |
|---|---|
| gross profit margin | 87.35% |
| operating profit margin | -519.75% |
| pretax profit margin | -511.9% |
| net profit margin | -511.9% |
| return on assets | -32.91% |
| return on equity | -71.66% |
| return on capital employed | -35.66% |
liquidity ratios | |
|---|---|
| current ratio | 15.39 |
| quick ratio | 15.32 |
| cash ratio | 14.51 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 197.88 |
| operating cycle | 413.22 |
| days of payables outstanding | 230.64 |
| cash conversion cycle | 182.58 |
| receivables turnover | 1.69 |
| payables turnover | 1.58 |
| inventory turnover | 1.84 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.10 |
| debt equity ratio | 0.12 |
| long term debt to capitalization | 0.10 |
| total debt to capitalization | 0.11 |
| interest coverage | -22.82 |
| cash flow to debt ratio | -2.66 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.97 |
| cash per share | 3.31 |
| operating cash flow per share | -0.92 |
| free cash flow operating cash flow ratio | 1.06 |
| cash flow coverage ratios | -2.66 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -17.06 |
Frequently Asked Questions
When was the last time Ocular Therapeutix, Inc. (NASDAQ:OCUL) reported earnings?
Ocular Therapeutix, Inc. (OCUL) published its most recent earnings results on 04-11-2025.
What is Ocular Therapeutix, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Ocular Therapeutix, Inc. (NASDAQ:OCUL)'s trailing twelve months ROE is -71.66%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Ocular Therapeutix, Inc. (OCUL) currently has a ROA of -32.91%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did OCUL's net profit margin stand at?
OCUL reported a profit margin of -511.9% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is OCUL's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 15.39 in the most recent quarter. The quick ratio stood at 15.32, with a Debt/Eq ratio of 0.12.